Use of biomolecular targets in the treatment and visualization of tumors
View Patent ↗The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
1. A method for identifying an agent that modulates an activity of TM7XN1 in an adenocarcinoma cell expressing TM7XN1, the method comprising:
contacting a candidate agent with an adenocarcinoma cell expressing a TM7XN1 polypeptide comprising the amino acid sequence set forth in SEQ ID No:2; and
determining whether there is an effect on the cell, indicating that the agent modulates an activity of TM7XN1.
2. The method of claim 1 , wherein the agent downregulates or upregulates expression of TM7XN1.
3. The method of claim 1 , wherein the agent inhibits or increases an activity of TM7XN1.
4. A method for identifying an agent that modulates an activity of TM7XN1 in a non-melanoma skin cancer cell expressing TM7XN1, the method comprising:
contacting a candidate agent with a non-melanoma skin cancer cell expressing a TM7XN1 polypeptide comprising the amino acid sequence set forth in SEQ ID No:2; and
determining whether there is an effect on the cell, indicating that the agent modulates an activity of TM7XN.
5. The method of claim 4 , wherein the agent downregulates or upregulates expression of TM7XN1.
6. The method of claim 4 , wherein the agent inhibits or increases activity of TM7XN1.
7. A method for identifying an agent that modulates activity of TM7XN1 in a renal carcinoma cell expressing TM7XN1, the method comprising:
contacting a candidate agent with a renal carcinoma cell expressing a TM7XN1 polypeptide comprising the amino acid sequence set forth in SEQ ID No:2; and
determining whether there is an effect on the cell, indicating that the agent modulates an activity of TM7XN.
8. The method of claim 7 , wherein the agent downregulates or upregulates expression of TM7XN1.
9. The method according to claim 7 , wherein the agent inhibits or increases an activity of TM7XN1.
10. The method of claim 1 , wherein modulation of TM7XN1 is measured by a change in intracellular calcium mobilization in said cell in an in vitro assay.
11. The method of claim 1 , wherein modulation of TM7XN1 is measured by a said change in concentration of cAMP.
12. The method of claim 1 , wherein modulation of TM7XN1 is measured by the ability of the cell to move through a matrix in an in vitro assay.
13. The method according to claim 1 , wherein modulation of TM7XN1 is measured by inhibition of apoptosis of said cells.
14. The method according to claim 1 , wherein modulation of TM7XN1 is measured by the expression of enzymes involved in matrix degradation in an in vitro assay.
15. The method of claim 4 , wherein modulation of TM7XN1 is measured by a change in intracellular calcium mobilization in said cell in an in vitro assay.
16. The method of claim 4 , wherein modulation of TM7XN1 is measured by a change in concentration of cAMP.
17. The method of claim 4 , wherein modulation of TM7XN1 is measured by the ability of the cell to move through a matrix in an in vitro invasion assay.
18. The method according to claim 4 , wherein modulation of TM7XN1 is measured by inhibition of apoptosis of the cell.
19. The method according to claim 4 , wherein modulation of TM7XN1 is measured by the expression of enzymes involved in matrix degradation in an in vitro assay.
20. The method of claim 7 , wherein modulation of TM7XN1 is measured by a change in intracellular calcium mobilization in said cell in an in vitro assay.
21. The method of claim 7 , wherein modulation of TM7XN1 is measured by a change in concentration of cAMP.
22. The method according to claim 7 , wherein modulation of TM7XN1 is measured by a change in the ability of the cell to move through a matrix in an in vitro invasion assay.
23. The method according to claim 7 , wherein modulation of TM7XN1 is measured by inhibition of apoptosis of said cells.
24. The method according to claim 7 , wherein modulation of TM7XN1 is measured by the expression of enzymes involved in matrix degradation in an in vitro assay.